Anna Skorupa
Medical University of Silesia
5 Papers
32 Citations
Anna Skorupa is an academic researcher from Medical University of Silesia. The author has contributed to research in topics: Cryopreservation & Insulin resistance. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Serum concentration of visfatin in obese women
Barbara Zahorska-Markiewicz,Magdalena Olszanecka-Glinianowicz,Joanna Janowska,Piotr Kocełak,Elżbieta Semik-Grabarczyk,Michał Holecki,Piotr Dąbrowski,Anna Skorupa +7 more
TL;DR: The observed increase of visfatin in obesity may be a counterregulation preventing further glucose increase, and positive correlations between serum concentrations of visFatin and insulin in the obese group were found.
143
•Journal Article
Plasma visfatin and tumor niecross factor-alpha (TNF-α) levels in metabolic syndrome
Magdalena Olszanecka-Glinianowicz,Piotr Kocełak,Joanna Janowska,Anna Skorupa,Marcin Nylec,Barbara Zahorska-Markiewicz +5 more
TL;DR: The findings suggest that visfatin in metabolic syndrome should be regarded as a proinflammatory factor indirectly favouring the development of insulin resistance.
Application of interval arithmetic in numerical modeling of cryopreservation process during cryoprotectant loading to microchamber
TL;DR: In this article , the authors present numerical modeling of the heat and mass exchange occurring in a two-dimensional axially symmetric articular cartilage sample submerged in a microchamber into CPTes2 bathing solution undergoing cryopreservation.
3
Comparison of heat transfer phenomena for two different cryopreservation methods: slow freezing and vitrification
TL;DR: In this article , Czestochowska et al. presented a paper on applied mathematics and computational mechanics, Prace Naukowe Instytutu Matematyki i Informatyki, Politechnika Częstochowskka, Scientific Research of the Institute of Mathematics and Computer Science, CZestochowa University of Technology
2
Hypercalcemia in Patients Treated with Oral Bisphosphonates for Tumor-Induced Osteolysis
TL;DR: Multiple myeloma, prostate and breast cancer are the most common causes of hypercalcemia of malignancy in patients with tumor-induced osteolysis starting therapy with bisphosphonates.